Vivozon Healthcare Registers First Patient in Domestic Phase 3 Trial of Non-Opioid Painkiller 'Opirangerin'

Sequential Patient Registration Scheduled at Four Major Hospitals by Early Next Month

[Asia Economy Reporter Kim Ji-hee] Vibozone Healthcare announced on the 21st that it has officially commenced Phase 3 clinical trials in South Korea for ‘Opiranzerin’ (VVZ-149) injection, a non-opioid analgesic developed by Vibozone.

On the 20th, Vibozone Healthcare registered the first patient for the clinical trial at Seoul Asan Medical Center, targeting patients experiencing pain after laparoscopic colectomy surgery. This clinical trial is being conducted at four major hospitals?Seoul National University Hospital, Korea University Anam Hospital, Bundang Seoul National University Hospital, and Seoul Asan Medical Center?with 300 colectomy patients participating. Seoul Asan Medical Center began patient registration first, and other institutions will sequentially register patients from this week through early next month.

Opiranzerin is a non-opioid analgesic with strong pain-relieving effects for moderate to severe pain, including postoperative pain. Being non-opioid and non-NSAID (non-steroidal anti-inflammatory drug), it offers the advantage of overcoming side effects associated with opioid analgesics or NSAIDs.

Colectomy is a surgery with a high level of pain intensity required for colon cancer patients, and opioid analgesics are essential during surgery to reduce pain. Opioid analgesics are drugs that manage severe pain that cannot be relieved by acetaminophen-based antipyretic analgesics like Tylenol or anti-inflammatory analgesics. However, in addition to side effects such as respiratory depression, constipation, and itching, there is a problem of opioid addiction when abused.

Lee Doo-hyun, Chairman of Vibozone Group, stated, “Despite COVID-19, we are making great efforts to ensure the smooth progress of the clinical trial,” and added, “Having confirmed the safety and efficacy of Opiranzerin through previous clinical trials, we expect positive results in this trial as well.”

Meanwhile, Vibozone Healthcare obtained the exclusive domestic license from Vibozone last October for the non-opioid analgesic new drug Opiranzerin injection and is conducting domestic clinical trials.

This content was produced with the assistance of AI translation services.